Tissue Repair & RecoveryPreclinical / anecdotal

Lysine Proline Valine

KPV, α MSH C terminal tripeptide

The C terminal tripeptide of α MSH, studied for anti inflammatory activity via NF-κB modulation, without the melanocortin or tanning effects of the parent hormone.

Anti inflammatory Gut health Wound healing

Lys-Pro-Val

Sequence

NF-κB

Target pathway

Preclinical

Human evidence

Mechanism of action

How KPV works

The anti inflammatory C terminal piece of α MSH, it calms NF-κB inflammatory signaling inside cells, without the tanning effects of the parent hormone.

KPV

α MSH C-terminus

Cell uptake

PepT1 transporter

NF-κB ↓

Inflammation

Mucosal calm

Gut and skin

Also studied

In mouse colitis models, oral KPV reduced inflammation and improved mucosal integrity via PepT1 mediated cellular uptake.

See related compounds

Inhibits NF-κB and MAP kinase signaling and lowers pro inflammatory cytokine secretion at nanomolar concentrations.

See related compounds

Explored for anti inflammatory wound healing applications; human efficacy is unproven.

See related compounds

Applications

Research applications

Intestinal inflammation

Colitis / IBD models

Animal (rodent) model

Mouse DSS / TNBS colitis

Anti inflammatory signaling

NF-κB / cytokines

In vitro / cell model

Cell models

Wound healing

Skin & mucosa

Animal (rodent) model

Preclinical

Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.

Compound data

Molecular profile

CAS number67727-97-3

Molecular formulaC16H30N4O4

Molecular weight342.43 g/mol

TypeTripeptide

SequenceLys-Pro-Val (KPV)

AppearanceWhite lyophilized powder

Literature

Key studies

Gastroenterology2008

PepT1 mediated tripeptide KPV uptake reduces intestinal inflammation

Dalmasso G, et al.

Key finding

Oral KPV reduced inflammation in two mouse colitis models via PepT1 mediated uptake, inhibiting NF-κB and pro inflammatory cytokines.

View on PubMed

Full profile

Evidence, safety & status

Claimed benefits & evidence

Anti inflammatory and gut healing claims (IBD, wound healing). Evidence is preclinical; no completed human efficacy trials.

Safety & dangers

Limited human safety data; gray market risk.

Regulatory status

Not FDA approved; Category 2 (2023), removed April 2026; PCAC review July 23, 2026 (wound healing and inflammatory conditions).

Administration

Oral/subcutaneous/topical in protocols.

Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. Anyone considering these compounds should consult a qualified physician.

For research use only

For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.